TERNS PHARMACEUTICALS INC (TERN)

US8808811074 - Common Stock

4.91  +0.27 (+5.82%)

After market: 4.86 -0.05 (-1.02%)

Fundamental Rating

3

Overall TERN gets a fundamental rating of 3 out of 10. We evaluated TERN against 198 industry peers in the Pharmaceuticals industry. While TERN has a great health rating, there are worries on its profitability. TERN is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

In the past year TERN has reported negative net income.
TERN had a negative operating cash flow in the past year.
TERN had negative earnings in each of the past 5 years.
TERN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of TERN (-33.60%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -35.33%, TERN is in the better half of the industry, outperforming 62.05% of the companies in the same industry.
Industry RankSector Rank
ROA -33.6%
ROE -35.33%
ROIC N/A
ROA(3y)-28.15%
ROA(5y)-80.67%
ROE(3y)-29.47%
ROE(5y)-352.95%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

TERN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

8

2. Health

2.1 Basic Checks

TERN has more shares outstanding than it did 1 year ago.
TERN has more shares outstanding than it did 5 years ago.
TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TERN has an Altman-Z score of 11.83. This indicates that TERN is financially healthy and has little risk of bankruptcy at the moment.
TERN has a better Altman-Z score (11.83) than 90.26% of its industry peers.
There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.83
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 22.39 indicates that TERN has no problem at all paying its short term obligations.
TERN's Current ratio of 22.39 is amongst the best of the industry. TERN outperforms 95.90% of its industry peers.
TERN has a Quick Ratio of 22.39. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
TERN has a Quick ratio of 22.39. This is amongst the best in the industry. TERN outperforms 96.41% of its industry peers.
Industry RankSector Rank
Current Ratio 22.39
Quick Ratio 22.39

1

3. Growth

3.1 Past

TERN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.60%, which is quite impressive.
EPS 1Y (TTM)30.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 3.43% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.92%
EPS Next 2Y-6.71%
EPS Next 3Y3.39%
EPS Next 5Y3.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

TERN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.71%
EPS Next 3Y3.39%

0

5. Dividend

5.1 Amount

No dividends for TERN!.
Industry RankSector Rank
Dividend Yield N/A

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (4/26/2024, 7:19:10 PM)

After market: 4.86 -0.05 (-1.02%)

4.91

+0.27 (+5.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap317.43M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -33.6%
ROE -35.33%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 22.39
Quick Ratio 22.39
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)30.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-10.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y